NEW YORK (GenomeWeb News) — Qiagen last week acquired Genaco Biomedical Products for $22 million in cash, the company said today.
 
Qiagen purchased 100 percent of the company’s outstanding stock, and will pay out as much as $18 million in milestone payments from anticipated grants.  
 
Genaco is an early-stage company that uses a proprietary PCR-based multiplexing technology, called TEM-PCR, in its Templex molecular diagnostics, Qiagen said.
 

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

A federal grand jury has indicted Elizabeth Holmes and Ramesh Balwani for alleged wire fraud in conjunction with their activities at Theranos.

Nature News reports that some developers are nervous about GitHub's acquisition by Microsoft.

A direct-to-consumer genetic testing company sent out used spit kits, CNBC reports.

In PLOS this week: comparison of commercial bisulfite kits, new method to predict essential proteins, and more